Pharmazz

About Pharmazz

Pharmazz is a clinical-stage biopharmaceutical company established in 2010, specializing in the development and commercialization of novel therapeutics for the critical care and hospital markets. The company was founded by Dr. Anil Gulati and Ajit Chand Srimal. Dr. Gulati, who serves as the Chairman and CEO, brings a wealth of experience from his distinguished academic career as a Professor Emeritus at Midwestern University and the University of Illinois at Chicago. His background as an inventor with over 50 patents has been instrumental in bridging academic research with pharmaceutical development, directly shaping the company's focus on first-in-class drugs for unmet medical needs like acute ischemic stroke and hypovolemic shock.

The company's business model centers on the discovery, development, and subsequent commercialization of its proprietary drug candidates. Pharmazz generates revenue through licensing agreements and royalties from its partners who market the approved drugs. A key part of its strategy involves outsourcing functions like manufacturing and marketing, allowing the company to focus on its core research and development activities. The firm primarily serves patients in critical care settings through partnerships with major pharmaceutical distributors. Key milestones include obtaining marketing authorization for its two lead products in India and gaining U.S. FDA approval to proceed with Phase III clinical trials for both candidates in the United States and Europe.

Pharmazz's portfolio is led by two first-in-class molecules: Centhaquine (brand name Lyfaquin®) for hypovolemic shock and Sovateltide (brand name Tyvalzi) for acute cerebral ischemic stroke. Centhaquine acts as a resuscitative agent with a unique mechanism; it stimulates α2B adrenergic receptors to constrict veins, which increases the volume of blood returning to the heart, thereby boosting cardiac output. Simultaneously, it acts on central α2A adrenergic receptors, which reduces sympathetic nervous system overactivity and improves blood flow to vital tissues. This dual action helps stabilize patients suffering from significant blood loss. Sovateltide is a selective endothelin-B receptor agonist designed to treat ischemic stroke. Its mechanism involves stimulating neural progenitor cells to promote the formation of new neurons and blood vessels, protecting neural mitochondria, and increasing cerebral blood flow. Pharmazz has established significant partnerships to commercialize these drugs in India, licensing Centhaquine to Dr. Reddy's Laboratories and Sovateltide to Sun Pharmaceutical Industries.